Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Ponzo who wrote (131)	1/16/1998 2:07:00 PM
From: ZChazz	Respond to of 550

Thanks for the excellent summary!

To: Kevin Ponzo who wrote (131)	1/16/1998 2:47:00 PM
From: BulbaMan	Respond to of 550

I agree SUGN is very undervalued. I heard their CEO Stephen Evans-Freke at the H&Q Biotech confab this week and thought he was one of the most impressive of those presenting. Long-term holders of SUGN stock should be highly rewarded. Thanks for your summary of the company.

To: Kevin Ponzo who wrote (131)	1/16/1998 11:11:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 550

Hi Kevin: First let me say that I am SUGN long and that your reading from press is to optimistic. Here are several points: 1. I will not count to much on Lehman reports and sales projection at this time. There are (from NCI) ~13 PIII and ~38 PII trials for brain cancer with dozen which are not included. So what will be SU 101 market penetration for brain and other indication is hard to project without more clinical data for comparison analysis. 2. Based on company press (18 month for enrollment [one patient per month per site], 6 month follow-up, 4 months for data analysis and FDA submission, 6 for FDA review and 2 for lunch) drug will not hit the market before Jan. 2001. So, I am not satisfied with this time-table and the only way to speed-up process is faster enrollment and/or early trials termination because of the sufficient clinical benefit at interim analysis. Is this possible? Yes, but there are no evidence that this probability are high, at this time. 3. Partner for territory other than NA? This will confirm drug value. 4. Without data from flk-1 PI trials and psoriasis PI/II trials investors are cautions about stock. Price, after secondary (at 16) never recovery, and where will go from here is big question? 5. Reporting old and no-event news (Astra milestone on Her projects) during H&Q conf. is hurting more than helping. Investor expected psoriasis trials data, partner for SU 101 or something more seriously. Also, regardless that Richard van den Broek complemented SUGN (with several other companies) on H&Q presentation, price move itself speak that presentation was week at least. I do not have info from presentation and can't comment. 6. Their cash position (after secondary) improved, but it will detoured rapidly after several advance cancer clinical trials. This trials are expensive (and long) so picking-up partner is very important at this late stage development cycle. It is true that SUGN has strong science potential and that their technology (REGN also has advance knowledge on TK/TP receptors, broad pipeline portfolio and very strong partner, still stock price performance is even worse than for SUGN) may bring valuable product on market. SUGN problems is shortage in diversified compounds library for screening (they have excellent assay and screen technology, IMO), so expanded collaboration with ARQL, new with PCOP, TRGA, and other combi-chem generator will be a big plus for them. Almost necessity. So, is current market capitalization in relation with SUGN position? I will say yes. If we have positive data from flk-1 and psoriasis, things will change dramatically, and price will too. On negative news (is current price performance ahead from negative news?) price will sunk. My SUGN long term position is based on their approach to cancer therapy. Many different targets and some of them will bring results. Ended I will preferred some change in their business approach (more collaboration and equals partnership) and I hope that my expectation will become reality. mz